Rate of misdiagnosis and clinical usefulness of the correct diagnosis in exudative neovascular maculopathy secondary to AMD versus pachychoroid disease.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 11 2020
Historique:
received: 29 09 2020
accepted: 04 11 2020
entrez: 24 11 2020
pubmed: 25 11 2020
medline: 30 3 2021
Statut: epublish

Résumé

The aim of this study was to explore the relative prevalence and clinical differences between age-related macular degeneration (AMD) and pachychoroid disease in patients older than 50 years with newly diagnosed exudative neovascular maculopathy, and also assess the rate of misdiagnosis between these two disorders. In this retrospective observational study, we reviewed data from patients 50 years of age and older with newly diagnosed treatment-naïve exudative macular neovascularization (MNV) secondary to AMD or pachychoroid disease. Of the 139 patients (139 eyes) who fulfilled the inclusion criteria, 35 patients were graded as being affected by pachychoroid disease complicated by exudative MNV and 104 subjects had neovascular AMD. Therefore, prevalence of pachychoroid disease complicated by exudative MNV was 25.2% (confidence interval-CI 18.2-33.2%). Mean ± SD age was 67.0 ± 8.8 years in the pachychoroid disease group and 80.6 ± 6.6 years in the neovascular AMD group (P < 0.0001). At baseline, BCVA was better in patients with pachychoroid disease complicated by exudative MNV (0.4 ± 0.3 LogMAR vs. 0.7 ± 0.5 LogMAR, P = 0.003). At the 1-year follow-up visit, BCVA was still better in patients with pachychoroid-associated MNV (0.34 ± 0.32 LogMAR vs. 0.59 ± 0.52 LogMAR; P = 0.005). In our study cohort, 19 patients were graded to be affected by pachychoroid disease complicated by exudative MNV even though a diagnosis of neovascular AMD was erroneously reported in their medical records at baseline. In conclusion, pachychoroid disease is a frequent cause of exudative MNV in aged patients with a high rate of misdiagnosis. A correct diagnosis may be important as these two disorders differ in terms of clinical characteristics and prognosis.

Identifiants

pubmed: 33230253
doi: 10.1038/s41598-020-77566-1
pii: 10.1038/s41598-020-77566-1
pmc: PMC7684296
doi:

Substances chimiques

VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
Ranibizumab ZL1R02VT79

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

20344

Références

Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):292-298
pubmed: 28114590
Retina. 2016 May;36(5):889-95
pubmed: 27115853
Retina. 2017 Feb;37(2):199-221
pubmed: 27749784
Retina. 2013 Sep;33(8):1659-72
pubmed: 23751942
Prog Retin Eye Res. 2019 Nov;73:100770
pubmed: 31319157
Retina. 2018 Aug;38(8):1464-1477
pubmed: 28704254
Retina. 2018 Apr;38(4):708-716
pubmed: 28505013
Prog Retin Eye Res. 2018 Nov;67:30-55
pubmed: 30059755
Jpn J Ophthalmol. 2020 Jul;64(4):323-337
pubmed: 32318919
Retina. 2012 Oct;32(9):1829-37
pubmed: 22850219
Pharmaceuticals (Basel). 2020 Aug 28;13(9):
pubmed: 32872388
Retina. 2018 Oct;38(10):1968-1976
pubmed: 29746411
J Clin Med. 2020 Jun 29;9(7):
pubmed: 32610483
Retina. 2015 Jan;35(1):1-9
pubmed: 25158945
Retina. 2020 Apr;40(4):657-662
pubmed: 31415450
Ophthalmol Retina. 2019 Dec;3(12):1013-1015
pubmed: 31810570
Int Ophthalmol. 2020 Dec;40(12):3577-3589
pubmed: 32729062
Sci Rep. 2015 Nov 06;5:16204
pubmed: 26542071
PLoS One. 2019 Feb 14;14(2):e0212055
pubmed: 30763369
Am J Ophthalmol. 2006 Mar;141(3):456-62
pubmed: 16490490
Ophthalmology. 2018 May;125(5):708-724
pubmed: 29331556
Retina. 2018 Sep;38(9):1652-1667
pubmed: 29135799
Clin Exp Ophthalmol. 2018 Mar;46(2):189-200
pubmed: 29178419
Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2133-41
pubmed: 22427567
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
Ophthalmol Retina. 2017 Jul - Aug;1(4):328-332
pubmed: 31047519
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4792-4798
pubmed: 28973325

Auteurs

Enrico Borrelli (E)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Milan, Italy.

Marco Battista (M)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Milan, Italy.

Francesco Gelormini (F)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Milan, Italy.

Riccardo Sacconi (R)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Milan, Italy.

Lea Querques (L)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Milan, Italy.

Giovanna Vella (G)

IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ophthalmology, Department of Surgical, Medical, Molecular Pathology and of Critical Area, University of Pisa, Pisa, Italy.

Chiara Viganò (C)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Milan, Italy.

Francesco Bandello (F)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Milan, Italy.

Giuseppe Querques (G)

Department of Ophthalmology, University Vita-Salute San Raffaele, Via Olgettina 60, Milan, Italy. giuseppe.querques@unisr.it.
IRCCS San Raffaele Scientific Institute, Milan, Italy. giuseppe.querques@unisr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH